Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
Status:
Not yet recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients
with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.